One part from the KOL meeting Apr 3, 2024 continues resonating...

One part from the KOL meeting Apr 3, 2024 continues resonating in my mind.

Dr. Arshad Khanani on the portion of study participants reaching 20/40 (00:44:20-00:45:00):
"I think it's important to look at the baseline VA. It's about about 50.5 letters for the P2b Programme and if you look at Eylea or Lucentis, it's close to 60."
"And even that 10 letter gap in baseline characteristics, we are getting a similar number of patients getting 20/40 which kind of shows the value of additional treatment."

When we check all trials' results:

LUCERNE (Vabysmo):
aflibercept (Eylea) q4w control 58.9 letters mean baseline (range 24-78 letters, 11.9% of patients enrolling with 74 letters or better)
=> 49.4% achieving 20/40 (= 69 letters) at 48w

TENEYA (Vabysmo):
aflib. control q4w 61.5 letters (24-78, 15.4% 74 letters or better)
=> 52.3% achieving 20/40 (69 letters) at 48w

HARRIER (Beovu):
aflib. control q4w 60.8 letters (23-78, 17.9% 73 letters or better)
=> 49.6% achieving 20/32 (73 letters) at 48w

HAWK (Beovu):
aflib. control q4w 60.0 letters (23-78, 19.2% 73 letters or better)
=> 50.8% achieving 20/32 (73 letters) at 48w

CATT (Avastin):
aflib. control q4w 60.1 letters (23-82, 36.9% 68 letters or better)
=> 67.3% achieving 20/40 (68 letters) at 1y
bevacizumab test q4w 60.2 letters (23-82, 32.9% 68 letters or better)
=> 67.5% achieving 20/40 (68 letters) at 1y

VIEW1+2 (Eylea) didn't measure this outcome
MARINA and ANCHOR (both Lucentis) didn't measure this outcome neither

P2b (sozinibercept):
ranibizumab (Lucentis) control q4w letters 50.7 letters (25-60 letters only)
=> 34.5% achieving 20/40 at 24w
sozinibercept 2.0 mg + ranib. q4w 49.5 letters (25-60 letters only)
=> 48.6% achieving 20/40 at 24w

So, these are the hard numbers behind of what Dr. Khanani means when saying the addition of sozinibercept gets a real-world patient with a 50 letters BCVA at start up to a 20/40 vision (= 68-69 letters) with the same probability as an anti-VEGF-A alone does with a 60 letters patient at start.

A lot of numbers to crunch. And it certainly takes some time to go through all of them. But the time invested is worth it to get the conviction that at the end of the day, some time in 2025 sozinibercept will show statistically and clinically meaningful results.